Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR425899 Receptor Occupancy Study in T2DM
NCT03350191Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2017
- Primary completion
- Jun 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bamadutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sanofi. Primary endpoint: Glucagon receptor occupancy at Day 20. Started Dec 2017; status: completed.
02
Drugs
bamadutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03350191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03350191.